155 related articles for article (PubMed ID: 28324747)
21. Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience.
Ghorani E; Wong HH; Hewitt C; Calder J; Corrie P; Basu B
Oncology; 2015; 89(5):281-7. PubMed ID: 26372905
[TBL] [Abstract][Full Text] [Related]
22. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.
Faris JE; Blaszkowsky LS; McDermott S; Guimaraes AR; Szymonifka J; Huynh MA; Ferrone CR; Wargo JA; Allen JN; Dias LE; Kwak EL; Lillemoe KD; Thayer SP; Murphy JE; Zhu AX; Sahani DV; Wo JY; Clark JW; Fernandez-del Castillo C; Ryan DP; Hong TS
Oncologist; 2013; 18(5):543-8. PubMed ID: 23657686
[TBL] [Abstract][Full Text] [Related]
23. Locally advanced anaplastic pancreatic adenocarcinoma with initial response to FOLFIRINOX and rapid progression after five months.
Shinagare AB; Ramaiya NH; Bellizzi AM; Mayer RJ
Pancreatology; 2012; 12(1):35-8. PubMed ID: 22487471
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma.
Tinchon C; Hubmann E; Pichler A; Keil F; Pichler M; Rabl H; Uggowitzer M; Jilek K; Leitner G; Bauernhofer T
Acta Oncol; 2013 Aug; 52(6):1231-3. PubMed ID: 23445338
[No Abstract] [Full Text] [Related]
25. Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability.
Mondo EL; Noel MS; Katz AW; Schoeniger LO; Hezel AF
J Clin Oncol; 2013 Jan; 31(3):e37-9. PubMed ID: 23233707
[No Abstract] [Full Text] [Related]
26. Impact of Granulocyte Colony-Stimulating Factor (G-CSF) on the Outcomes of Patients With Metastatic Pancreatic Adenocarcinoma (MPA) During First-Line Treatment With FOLFIRINOX: A Single-Center Retrospective Analysis.
Carvalho de Brito AB; Riechelmann RP; Fonseca de Jesus VH
Cancer Control; 2023; 30():10732748221149543. PubMed ID: 36592369
[TBL] [Abstract][Full Text] [Related]
27. ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis.
Strippoli A; Rossi S; Martini M; Basso M; D'Argento E; Schinzari G; Barile R; Cassano A; Barone C
Oncotarget; 2016 Jun; 7(23):35159-68. PubMed ID: 27147577
[TBL] [Abstract][Full Text] [Related]
28. FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study.
Umemoto K; Takahashi H; Morizane C; Yamada I; Shimizu S; Shioji K; Yoshida Y; Motoya M; Mizuno N; Kojima Y; Terashima T; Uesugi K; Ueno M; Furuse J; Akimoto T; Ikeda M
Cancer Chemother Pharmacol; 2021 Mar; 87(3):397-404. PubMed ID: 33386925
[TBL] [Abstract][Full Text] [Related]
29. Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review.
Hohla F; Hopfinger G; Romeder F; Rinnerthaler G; Bezan A; Stättner S; Hauser-Kronberger C; Ulmer H; Greil R
Int J Oncol; 2014 Jan; 44(1):319-26. PubMed ID: 24247204
[TBL] [Abstract][Full Text] [Related]
30. Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer.
Rombouts SJ; Walma MS; Vogel JA; van Rijssen LB; Wilmink JW; Mohammad NH; van Santvoort HC; Molenaar IQ; Besselink MG
Ann Surg Oncol; 2016 Dec; 23(13):4352-4360. PubMed ID: 27370653
[TBL] [Abstract][Full Text] [Related]
31. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
[TBL] [Abstract][Full Text] [Related]
32. Complete radiological response of an initially locally advanced unresectable pancreatic cancer to chemoradiotherapy using FOLFIRINOX regimen: report of a case.
Turner K; Levi Sandri GB; Boucher E; Hénno S; Le Prisé E; Meunier B; Boudjema K; Sulpice L
Clin Res Hepatol Gastroenterol; 2015 Apr; 39(2):e29-31. PubMed ID: 25288453
[No Abstract] [Full Text] [Related]
33. FOLFIRINOX as first-line treatment for unresectable acinar cell carcinoma of the pancreas: a case report.
Schempf U; Sipos B; König C; Malek NP; Bitzer M; Plentz RR
Z Gastroenterol; 2014 Feb; 52(2):200-3. PubMed ID: 24526405
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and Tolerability of Maintenance Capecitabine Administrated to Patients with Metastatic Pancreatic Cancer Treated with First-Line FOLFIRINOX.
Reure J; Follana P; Gal J; Evesque L; Cavaglione G; Saint A; François E
Oncology; 2016; 90(5):261-6. PubMed ID: 27097162
[TBL] [Abstract][Full Text] [Related]
35. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study.
Conroy T; Paillot B; François E; Bugat R; Jacob JH; Stein U; Nasca S; Metges JP; Rixe O; Michel P; Magherini E; Hua A; Deplanque G
J Clin Oncol; 2005 Feb; 23(6):1228-36. PubMed ID: 15718320
[TBL] [Abstract][Full Text] [Related]
36. Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach.
Macaire P; Paris J; Vincent J; Ghiringhelli F; Bengrine-Lefevre L; Schmitt A
Br J Clin Pharmacol; 2020 Dec; 86(12):2473-2485. PubMed ID: 32386071
[TBL] [Abstract][Full Text] [Related]
37. Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX.
Zhu J; Strosberg JR; Dropkin E; Strickler JH
J Gastrointest Cancer; 2015 Jun; 46(2):166-9. PubMed ID: 25662891
[No Abstract] [Full Text] [Related]
38. FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?
Kim R
Lancet Oncol; 2011 Jan; 12(1):8-9. PubMed ID: 21050812
[No Abstract] [Full Text] [Related]
39. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan.
Matsumoto I; Kamei K; Omae K; Suzuki S; Matsuoka H; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi M; Todaka A; Fukutomi A
Pancreatology; 2019 Mar; 19(2):296-301. PubMed ID: 30638853
[TBL] [Abstract][Full Text] [Related]
40. Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study.
Ho MY; Kennecke HF; Renouf DJ; Cheung WY; Lim HJ; Gill S
Am J Clin Oncol; 2017 Dec; 40(6):552-554. PubMed ID: 26165420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
